Focused On-demand Library for Acidic fibroblast growth factor intracellular-binding protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O43427

UPID:

FIBP_HUMAN

Alternative names:

FGF-1 intracellular-binding protein

Alternative UPACC:

O43427; A8K0J7; Q27Q85; Q6IBQ3; Q9HD65

Background:

The Acidic fibroblast growth factor intracellular-binding protein, alternatively known as FGF-1 intracellular-binding protein, plays a pivotal role in cellular growth processes. It is implicated in the mediation of FGF-signaling, crucial for embryonic development and establishing laterality. Its interaction with IER2 and involvement in mitogenic function underscore its significance in cellular signaling pathways.

Therapeutic significance:

Linked to Thauvin-Robinet-Faivre syndrome, a rare genetic disorder characterized by overgrowth, developmental delays, and various congenital abnormalities, this protein's genetic variants offer insights into disease mechanisms. Understanding the role of Acidic fibroblast growth factor intracellular-binding protein could open doors to potential therapeutic strategies for managing and treating this complex syndrome.